AI Article Synopsis
- Multiple myeloma is a terminal cancer that affects plasma cells, and a study reviewed patient survival in Western Australia over a decade.
- The research found no significant difference in survival rates between patients from metropolitan Perth and those from regional areas, despite fewer haematology services in rural locations.
- Patients diagnosed with R-ISS Stage 3 multiple myeloma had the lowest median survival time of 24 months in the study.
Article Abstract
Multiple myeloma is an incurable malignancy of plasma cells. We retrospectively reviewed the survival outcomes of patients with multiple myeloma in Western Australia (WA) public hospitals over a 10-year period. We did not detect a difference in survival between patients residing the metropolitan Perth and regional areas, despite a paucity of haematology services in regional WA due to low population density in a large geographic area. Patients with R-ISS Stage 3 had the poorest survival in our cohort with median survival of 24 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/imj.14905 | DOI Listing |
Publication Analysis
Top Keywords
multiple myeloma
12
patients multiple
8
western australia
8
survival
5
patients
4
myeloma large
4
large catchment
4
catchment square
4
square kilometres
4
kilometres western
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!